Adjuvant chemotherapy and radiotherapy showed no significant impact on local recurrence-free survival or overall survival in patients with localized myxofibrosarcoma after surgery over a median 89-month follow-up.
Observational (n=116)
No
Does adjuvant therapy improve outcomes in patients with localized myxofibrosarcoma?
Effect estimate: Adjuvant chemotherapy aHR for LFS 1.02 (95% CI: 0.53-1.98), aHR for OS 0.99 (95% CI: 0.38-2.61); Adjuvant radiotherapy aHR for LFS 1.11 (95% CI: 0.60-2.03), aHR for OS 0.90 (95% CI: 0.42-1.91)
Localized myxofibrosarcoma (MFS) is a rare soft tissue sarcoma with a high risk of local recurrence. However, the clinical benefit of adjuvant therapy remains controversial, particularly among Korean patients. This study aimed to evaluate the impact of adjuvant treatment and to identify prognostic factors in patients with localized MFS.
Kong et al. (Sun,) conducted a observational in Patients with localized myxofibrosarcoma (n=116). Adjuvant chemotherapy and/or radiotherapy vs. No adjuvant therapy was evaluated on Local recurrence-free survival (LFS) and overall survival (OS) (Adjuvant chemotherapy aHR for LFS 1.02 (95% CI: 0.53-1.98), aHR for OS 0.99 (95% CI: 0.38-2.61); Adjuvant radiotherapy aHR for LFS 1.11 (95% CI: 0.60-2.03), aHR for OS 0.90 (95% CI: 0.42-1.91)). Adjuvant chemotherapy and radiotherapy showed no significant impact on local recurrence-free survival or overall survival in patients with localized myxofibrosarcoma after surgery over a median 89-month follow-up.